**Model Letter For HIDA Members**

We encourage you to use this text to guide your own original letter that includes specific details of your business and its role in the medical supply chain. Please do not copy and paste the letter.

October XX, 2025

*By Electronic Submission* FR Doc: BIS-2025-0258

Julia A. Khersonsky

Deputy Assistant Secretary for Strategic Trade

Bureau of Industry and Security

Department of Commerce

1401 Constitution Ave. NW

Washington, DC 20230

Re: Notice of Request for Public Section 232 National Security Investigation of Imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices

Dear Ms. Khersonsky:

On behalf of [Company], I offer this response to the Department of Commerce’s request for comments on the Section 232 national security investigation on imports of personal protective equipment (PPE), medical consumables, and medical equipment*.*

*[Describe your company. How many employees do you have? What customers do you serve? Have tariffs forced you to cut services or delay investments? Do you manufacture or distribute domestic products you can spotlight?]*

Healthcare distributors are an essential link in the medical supply chain for small-market and rural healthcare providers – the very hospitals, doctors' offices, and nursing homes that are under pressure from other economic and policy changes in healthcare. Margins in healthcare distribution are small, and the cost increases tariffs impose on medical products cannot be absorbed forever. Many healthcare distributors are operating at a loss due to tariffs.

The right tariff policies can help domestic manufacturing.Tariffs levied during President Trump's first term have had a positive effect. The pandemic prompted the medical supply chain to further reassess an over-reliance on products from China. In subsequent years, medical manufacturers have moved out of China to other countries around the globe.

The wrong tariff policies will strain the medical supply chain.Country-specific reciprocal tariffs on imported raw materials make it more expensive to continue medical product manufacturing in the United States. Ironically, more tariffs would harm domestic manufacturers more than they would help. Any additional tariffs from Section 232 would make the medical supply chain unsustainable. Without time to adjust, patient care would be put at risk.

Thank you for the opportunity to comment as part of this investigation. [Company] greatly values the Administration’s ongoing commitment to supporting a resilient medical supply chain to protect our national security.

Sincerely,